Competing risk analyses in 115 patients with available SMIC monitoring (69 patients have died). (A) Cumulative incidence of response categories after first-line treatment in patients with symptomatic WM. (B) Cumulative incidence of progression after first-line treatment (87 progressions were recorded, and 21patients died before the occurrence of progression). (C) Cumulative incidence of second treatment initiation after first-line treatment (64 patients required a second-line treatment, and 27 patients died before receiving second-line treatment). (D) Cumulative incidences of related and unrelated death (the competing risk was death unrelated or without definitive conclusion and death unrelated or without definitive conclusion, respectively).